Altre lingue BioVaxys Technology Corp. OTC Markets

Azioni

BVAXF

CA09076M1014

Tempo differito OTC Markets Altri mercati azionari 18:44:47 16/07/2024			Variaz. 5gg	Var. 1 gen.
0,0479 ^USD	-7,71%		-8,76%	+16,83%

10/07	BioVaxys Technology Corp. riporta i risultati degli utili per il secondo trimestre e i sei mesi conclusi il 30 aprile 2024	CI
10/07	BioVaxys Technology Corp. riporta i risultati degli utili per il primo trimestre conclusosi il 31 gennaio 2024	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Canadian Investment Regulatory Organization Trade Resumption - BIOV	16:21
BioVaxys Technology Corp. Announces Revocation of Cease Trade Order	12/07
BioVaxys Technology Corp. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2024	10/07
BioVaxys Technology Corp. Reports Earnings Results for the First Quarter Ended January 31, 2024	10/07
BioVaxys Technology Corp. Reports Earnings Results for the Full Year Ended October 31, 2023	09/07
BioVaxys Technology Corp. Announces Failure to File Cease Trade Order	16/05
CSE Bulletin: Suspension - BioVaxys Technology Corp. (BIOV)	16/05
Canadian Investment Regulatory Organization Trading Halt - BIOV	16/05
BioVaxys Technology Corp. Closes SECOND Tranche of Private Placement	10/05
BioVaxys Technology Corp. Closes First Tranche of Private Placement	04/05
Biovaxys Technology Corp. Delays to File Its Interim Financial Statements for the Three Months Ended January 31, 2024	02/05
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update	02/05
Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050	01/05
BioVaxys Technology Corp. Appoints Christopher Cherry as Chief Financial Officer	30/04
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update	18/04
Biovaxys and SpayVac-For-Wildlife, Inc. Announce Launch of Field Trial for Large-Scale Immunocontraception in the Commercial Aquatic Farming Industry	10/04
BIOVAXYS AND SPAYVAC-FOR-WILDLIFE, INC. ANNOUNCE LAUNCH OF FIELD TRIAL FOR LARGE-SCALE IMMUNOCONTRACEPTION IN THE COMMERCIAL AQUATIC FARMING INDUSTRY	10/04
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update	05/04
BioVaxys Announces Allowance of DPX Formulation Patent for the United States and Filing of Additional International Patent Applications for Phase 1 DPX SurMage	03/04
BioVaxys Technology Plans Private Placement; Down 5.9%	25/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue BioVaxys Technology Corp. OTC Markets

Azioni

BVAXF

CA09076M1014

Altre lingue

Filtri